03:24 AM EDT, 10/30/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) logged $3.12 billion in profit attributable to owners of the parent for the third quarter, compared with $2.53 billion a year ago. EPS moved to $2 from $1.62, a Friday filing showed. For the three months ended Sept. 30, total revenue was $16.21 billion versus $15.19 billion, the London- and Stockholm-listed drugmaker added. Analysts polled by FactSet were expecting $12.03 billion in sales, $3.03 billion in net income, and $1.90 in EPS. For full-year 2026, AstraZeneca maintained its forecast of mid-to-high single-digit percentage growth in total revenue and a low double-digit percentage increase in core EPS.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.